SSShinichi Sato

Shinichi Sato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shinichi Sato has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Kazuhiko Takehara

    Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan

    11 shared publications
  • Minoru Hasegawa

    Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan

    11 shared publications
  • Manabu Fujimoto

    Department of Dermatology The University of Osaka Graduate School of Medicine Suita Japan

    7 shared publications
  • K Takehara

    Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

    6 shared publications
  • M Hasegawa

    Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

    5 shared publications
  • Ikuko Hayakawa

    Department of Dermatology, Kanazawa University, Graduate School of Medical Science, 13-1 Takaramachi, Ishikawa 920-8641 Kanazawa, Japan

    4 shared publications

Latest Publications

  • Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis

    by Shinichi Sato, Manabu Fujimoto, Minoru Hasegawa, Kazuhiko Takehara, Thomas F. Tedder


  • Open Access

    Role of C‐C chemokine receptors 1 and 5 and CCL3/macrophage inflammatory protein‐1α in the cutaneous Arthus reaction: possible attenuation of their inhibitory effects by compensatory chemokine production

    by Koichi Yanaba, Naofumi Mukaida, Kouji Matsushima, Philip M. Murphy, Kazuhiko Takehara, Shinichi Sato

    The deposition of immune complexes induces an acute inflammatory response with tissue injury. Immune complex‐induced tissue injury is mediated by inflammatory cell infiltration that is highly regulated by multiple chemokines. To assess the role of the chemokine receptors CCR1 and CCR5, and a ligand for these receptors CCL3/macrophage inflammatory protein‐1α, in this pathogenic process, the reverse passive cutaneous Arthus reaction was induced in mice lacking CCR1, CCR5, or CCL3. Edema was significantly attenuated in CCR1‐deficient (CCR1–/–) and CCL3–/– mice but not CCR5–/– mice, compared with wild‐type mice. Numbers of infiltrating neutrophils and mast cells were reduced in CCL3–/– and CCR1–/– mice, respectively, compared with wild‐type mice. CCR1 and CCR5 were expressed on neutrophils and mast cells. Remarkably, the intradermal mRNA expression of CCL5/RANTES, another ligand for CCR1 and CCR5, was increased in CCR5–/– and CCL3–/– mice, compared with wild‐type mice, while the cutaneous CCL3 mRNA expression was augmented in CCR1–/– and CCR5–/– mice. These results indicate that CCR1, CCR5, and CCL3 cooperatively contribute to the cutaneous Arthus reaction, and also suggest that enhanced expression of CCL3 and CCL5 compensates for the loss of CCR1, CCR5, and CCL3 in the reaction.


  • Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis

    by Shinichi Sato, Manabu Fujimoto, Minoru Hasegawa, Kazuhiko Takehara, Thomas F. Tedder


  • Open Access

    Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis

    by S. Sato, M. Fujimoto, M. Hasegawa, K. Komura, K. Yanaba, I. Hayakawa, T. Matsushita, K. Takehara

    Objective. To determine serum levels of soluble cytotoxic T-lymphocyte associated molecule-4 (sCTLA-4) and clinical association in patients with systemic sclerosis (SSc). Methods. Serum sCTLA-4 levels from 32 patients with diffuse cutaneous SSc (dSSc) and 27 patients with limited cutaneous SSc (lSSc) were examined by enzyme-linked immunosorbent assay (ELISA). For a longitudinal study, 211 sera from 30 SSc patients were analysed (follow-up 2.1–7.0 yr). Results. Serum sCTLA-4 levels were elevated in dSSc patients compared with normal controls (n = 41), lSSc patients and patients with active systemic lupus erythematosus (SLE) (n = 23). By contrast, sCTLA-4 levels in patients with lSSc or SLE were normal. SSc patients with elevated sCTLA-4 levels had a shorter disease duration and more frequent presence of digital pitting scars, contracture of phalanges, diffuse pigmentation, pulmonary fibrosis and decreased percentage vital capacity (%VC) than those with normal sCTLA-4 levels. sCTLA-4 levels correlated positively with the extent of skin fibrosis, serum IgG levels and anti-topoisomerase I antibody levels. In a longitudinal study, sCTLA-4 levels decreased on a parallel with improvement of skin sclerosis in five dSSc patients. Skin sclerosis did not improve in two of six dSSc patients with high sCTLA-4 levels throughout the follow-up, while the remaining four patients showed improvement of skin sclerosis. Conclusion. These results suggest that sCTLA-4 correlates with disease severity and activity of SSc and that sCTLA-4 plays a role in immunological abnormalities of SSc, since sCTLA-4 may augment humoral immune responses as well as T-cell responses by interfering with B7-CTLA-4 interactions that induce negative signals in T and B cells.


  • Open Access

    Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells

    by Shinichi Sato, Manabu Fujimoto, Minoru Hasegawa, Kazukiko Takehara

    Objective: To determine phenotypic and functional abnormalities of blood B cell subsets in patients with systemic sclerosis (SSc).Methods: Cell surface marker expression was determined by flow cytometry. Spontaneous apoptosis was evaluated by annexin V expression with flow cytometric analysis. IgG production by isolated IgD− memory B cells was examined by enzyme‐linked immunosorbent assay.Results: The numbers of blood CD27− naive B cells from SSc patients were increased compared with normal control cells, while memory B cells expressing medium levels of CD27 and plasmablasts expressing high levels of CD27 were reduced. In contrast, plasmablasts were the predominant population in patients with systemic lupus erythematosus (SLE). Memory B cells in SSc showed increased expression of activation markers, including CD80, CD86, and CD95, relative to normal controls. Consistent with CD95 up‐regulation, SSc memory B cells exhibited augmented spontaneous apoptosis after 24‐hour incubation; augmented apoptosis may explain the reduced memory B cell number. Nonetheless, isolated IgD− SSc memory B cells treated with stimuli had an enhanced ability to produce IgG. Furthermore, expression of CD19, a critical signal transduction molecule of B cells that regulates autoantibody production, was significantly increased in memory B cells as well as in naive B cells in SSc. In contrast, CD19 expression was decreased in SLE B cells.Conclusion: SSc patients have distinct abnormalities of blood homeostasis and B cell compartments, characterized by expanded naive B cells and activated but diminished memory B cells. Our results suggest that CD19 overexpression in SSc memory B cells is related to their hyperreactivity.


  • A case of scleroderma spectrum disorder with anticentriole antibody and pulmonary hypertension

    by Shinichi Sato, Minoru Hasegawa, Takeshi Echigo, Kazuhiko Takehara, Ikuko Hayakawa

    We describe the case of a patient with anticentriole antibody-positive scleroderma spectrum disorder (SSD) who developed pulmonary hypertension. A 54-year-old woman had noticed Raynaud's phenomenon and digital ulcers during the winter for the past 10 years. Although sclerodactyly was not present, digital ulcers, swelling of her hands, and phalangeal contracture were observed. An indirect immunofluorescence test revealed anticentriole antibody. Other SSc-specific antoantibodies were negative. An echocardiogram demonstrated that the estimated right ventricular systolic pressure was increased to 51 mmHg. She was diagnosed as SSD with pulmonary hypertension. This is the first case of SSD with anticentriole antibody to develop pulmonary hypertension.


  • Open Access

    Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis

    by K Yanaba, K Takehara, S Sato

    Objective: To determine serum concentrations of soluble P-selectin glycoprotein ligand-1 (sPSGL-1) and its clinical associations in patients with systemic sclerosis. Methods: Serum sPSGL-1 concentrations from 65 patients with systemic sclerosis were examined by enzyme linked immunosorbent assay. In a retrospective longitudinal study, 177 sera from 35 patients with systemic sclerosis were analysed (follow up 0.3 to 6.3 years) Results: Serum sPSGL-1 was raised in patients with limited cutaneous systemic sclerosis (lSSc) (n = 34) and diffuse cutaneous systemic sclerosis (dSSc) (n = 31) compared with healthy controls (n = 22) and patients with systemic lupus erythematosus (n = 20) or dermatomyositis (n = 20). Patients with systemic sclerosis who had raised sPSGL-1 concentrations less often had pulmonary fibrosis and decreased vital capacity (%VC) than those with normal sPSGL-1 levels. sPSGL-1 concentrations were positively correlated with %VC in patients with systemic sclerosis. In the longitudinal study, patients with systemic sclerosis but without pulmonary fibrosis had consistently increased sPSGL-1 concentrations in the early phase, while those with pulmonary fibrosis had decreased sPSGL-1 throughout the follow up period. Conclusions: A raised serum sPSGL-1 is associated with a lower frequency and severity of pulmonary fibrosis in systemic sclerosis. sPSGL-1 could be a protective factor against the development of pulmonary fibrosis in this disease and as such would be a possible therapeutic target.


  • Improvement of skin sclerosis after occurrence of anticentromere antibody in a patient with diffuse cutaneous systemic sclerosis

    by Ikuko Hayakawa, Shinichi Sato, Takeshi Echigo, Fumiaki Shirasaki, Minoru Hasegawa, Kazuhiko Takehara

    A 38-year-old woman had noticed sclerodactylia and Raynaud’s phenomenon 10 months before consultation. She was diagnosed as having systemic sclerosis (SSc) based on the skin sclerosis of her arms, chest, and face. Antinuclear antibody (ANA) level was 1:1280 with a speckled pattern, but specific autoantibodies were negative. Following the treatment with oral prednisolone and D-penicillamine, her skin sclerosis gradually improved. Three months after initiation of prednisolone, she presented Pneumocystis carinii pneumonia. About 1 year after the first admission, the pattern of indirect immunofluorescence staining changed from the speckled pattern to the discrete speckled pattern, and simultaneously anticentromere antibody (ACA) was detected by enzyme-linked immunosorbent assay. Her skin sclerosis rapidly and remarkably improved after appearance of ACA. It is generally considered that once certain SSc-specific autoantibody occurs, it does not disappear and change into other specificity of autoantibody thereafter. This case suggests that the presence of ACA closely correlates with clinical features and also suggests that clinical features may change during the clinical course with the appearance of another specific ANA. This case is very rare because such a case was not reported previously.


  • Open Access

    Anti‐DNA topoisomerase IIα autoantibodies in localized scleroderma

    by Ikuko Hayakawa, Minoru Hasegawa, Kazuhiko Takehara, Shinichi Sato

    Objective: To determine the prevalence and clinical correlation of anti‐DNA topoisomerase IIα (anti–topo IIα) antibody in patients with localized scleroderma.Methods: Anti–topo IIα antibodies or anti‐DNA topoisomerase I (topo I) antibodies were determined by enzyme‐linked immunosorbent assay (ELISA) and immunoblotting. Inhibition of topo IIα enzymatic activity by the antibodies was evaluated by decatenation assays using kinetoplast DNA as a substrate.Results: IgG or IgM anti–topo IIα antibody was detected in 76% (35 of 46) of patients with localized scleroderma, and in 85% (11 of 13) of patients with generalized morphea, the severest form of localized scleroderma. This prevalence of the antibody in patients with localized scleroderma was much higher than that found in patients with systemic sclerosis (SSc) (5 of 37 [14%]), systemic lupus erythematosus (2 of 26 [8%]), dermatomyositis (2 of 20 [10%]), and in healthy controls (3 of 42 [7%]). Immunoblotting confirmed the presence of IgG anti–topo IIα antibody in sera from patients with localized scleroderma and showed no cross‐reactivity of anti–topo IIα antibody with topo I. Anti–topo I antibody was not detected by ELISA in any sera from patients with localized scleroderma. In addition, anti–topo I antibody from SSc patients did not cross‐react with topo IIα. The presence of anti–topo IIα antibody was associated with a greater total number of sclerotic lesions and number of plaque lesions in patients with localized scleroderma. Furthermore, anti–topo IIα antibody was able to inhibit topo IIα enzymatic activity.Conclusion: The results of the present study indicate that anti–topo IIα is a major autoantibody in localized scleroderma, and is distinct from anti–topo I antibody in SSc.


  • Open Access

    Antiphospholipid antibody in localised scleroderma

    by S Sato, M Fujimoto, M Hasegawa, K Takehara

    Objective: To investigate the prevalence and clinical correlation of antiphospholipid antibodies in localised scleroderma. Methods: Antibodies against cardiolipin (aCL) or β2-glycoprotein I were examined by enzyme linked immunosorbent assay (ELISA) in 48 patients with localised scleroderma (18 patients with generalised morphoea, 20 with linear scleroderma, and 10 with morphoea). Twenty one of these patients were investigated for lupus anticoagulant (LAC) by screening and confirmatory coagulation tests. Results: Patients with generalised morphoea, the severest form of localised scleroderma, had significantly raised levels of IgM or IgG aCL relative to normal controls (n=21) and patients with systemic sclerosis (n=20). The IgM isotype was predominant, with the frequency of IgM aCL (61%) higher than that of IgG aCL (28%). Levels of aCL were similar for patients with linear scleroderma or morphoea and normal controls. IgM aCL were associated with a greater number of lesions, especially plaque lesions, wider distribution of lesions, and the presence of immunological abnormalities including antinuclear antibodies, rheumatoid factor, IgM antihistone antibodies, IgG anti-single stranded DNA antibodies, and raised serum interleukin 6 levels in patients with localised scleroderma. LAC was detected in 5/7 (71%) patients with generalised morphoea. However, pulmonary embolism was seen in only one patient with generalised morphoea. None of patients with localised scleroderma exhibited anti-β2-glycoprotein I antibodies. Conclusions: These results suggest that aCL and LAC are the major autoantibodies in patients with generalised morphoea.